CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Third-generation fluoroquinolone
Updated · Methodology
Mechanism
Levofloxacin, like some other fluoroquinolones, is associated with QT prolongation on the electrocardiogram and with infrequent cases of arrhythmia, and post-marketing reports describe rare cases of torsade de pointes (levofloxacin label, US Food and Drug Administration, FDA). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or inhibitors of the enzyme CYP3A4 (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish domperidone SmPC attributes the contraindication of such combinations to a higher risk of QT prolongation from pharmacodynamic or pharmacokinetic interactions and lists levofloxacin among the contraindicated antibiotics (AEMPS). Neither drug's documents describe a metabolic interaction between them.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Rare effects of levofloxacin include fast heart rate and palpitations. Effects of unknown frequency include QT prolongation, ventricular arrhythmia and torsade de pointes, mostly in people with risk factors for QT prolongation, and ventricular tachycardia that may lead to cardiac arrest (levofloxacin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS), and older people and women may be more sensitive to QT-prolonging drugs (levofloxacin SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names levofloxacin among these antibiotics (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The levofloxacin documents do not name domperidone. The Spanish levofloxacin SmPC says to use levofloxacin with caution together with other QT-prolonging drugs, in congenital long QT syndrome, uncorrected low potassium or magnesium and heart disease, and in older people and women (levofloxacin SmPC, AEMPS). The US label says to avoid levofloxacin in known QT prolongation, low potassium and with other QT-prolonging drugs (levofloxacin label, US Food and Drug Administration, FDA). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). Use domperidone at the lowest effective dose, no more than 30 mg a day in adults, and usually for no longer than one week (domperidone SmPC, AEMPS). If domperidone and levofloxacin have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Levofloxacin tablets (Chartwell RX) – prescribing information (2026)– FDA label, Chartwell RX, DailyMed setid 5c6c117c-9d91-48f4-9aaa-ee70b99218c2, version 3, 06/2026, section 5.11 (Prolongation of the QT Interval)
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Levofloxacino, Tavanic 500 mg (nº registro 62065), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62065 (Tavanic 500 mg comprimidos recubiertos con película, Sanofi Aventis), revisión 08/2026, secciones 4.3, 4.4, 4.5, 4.8 y 4.9